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Abstract 
 
The story of gastric acid secretion had begun with early ideas on gastric secretion 
(Spallanzani and de Reaumur, 17th century) and with first descriptions of food digestion 
(Dupuytren and Bichat, Beaumont, early 18th century), followed by proof that gastric juice 
contained acid (Prout, early 18th century). The research continued with first descriptions of 
gastric glands as the source of gastric acid and its changes upon digestive stimulus (Purkinje 
and Golgi, mid and late 19th century). The theory of "nervism" – the neuro-reflex stimulation 
of gastric secretion by vagal nerve (Pavlov, early 20th century) was contrasted by histamine 
mediated concept of gastric secretion (Popielsky and Code, mid 20th century). Thus, gastric 
acid and pepsin (Schwann, early 19th century) were found to be essential for food digestion 
and studies also pointed to histamine, being the most potent final common chemostimulator 
of oxyntic cells. The discoveries in etiopathogenesis of mucosal injury were marked by 
famous dictum: "No acid, no ulcer" ("Ohne saueren Magensaft kein peptisches Geschwuer", 
Schwarz, 1910) that later induced the term of "mucosal defence" and notion that the breaking 
of "gastric mucosal barrier" represents the initial step in the process of mucosal injury 
(Davenport, Code and Scholer, mid 20th century). The prostaglandins were shown to 
influence all major components of gastric mucosal barrier, described with term 
"cytoprotection" (Vane, Robert and Jacobson, 1970s). Beginning in the latter half of 19th 
century, the studies on gastric bacteriology that followed enabled discovery of association 
between Campylobacter (Helicobacter) pylori and peptic ulcers (Warren and Marshall, 
1980s) thal led to worldwide major interventions in treating  peptic ulcer disease. Surgical 
approach to peptic ulcer had been outlined by resection procedures (Billroth, Pean, 
Moynihan, late 19 century) and vagotomy, with or without drainge procedures (Jaboulay, 
Latarjet, Dragstedt, mid 20th century). Antacids, protective agents, anticholinergics, and later 
gastrin antagonists and prostaglandins were used for decades in treatment of peptic ulcer, 
with differing effects. The advent of the concept of H2 receptor antagonists (Black, 1970s) 
and discovery of acid (proton) pumps in parietal cells (Ganser, Forte and Sachs, late 1970s) 
paved the way for potent (H2 antagonists) and profound acid inhibition (proton pump 
inhibitors) that revolutionized the treatment of acid related disorders, including peptic ulcer 
disease. Worldwide, peptic ulcer and its complications remain the cause of  significant 
morbidity, especially in older age groups, representing a major burden for ambulatory and 
hospital healthcare resources.          
 
 
 
"Have we reached the zenith in our understanding of gastric acid physiology and the 
development of pharmacology  treatment for acid peptic disorders? 
We do not think so. 
This disorders remain prominent, and there is much still to be discovered by future clinical 
and basic investigators." 
 
     Mitchell L. Schubert and David A. Peura 
       Gastroenterology 2008;134:1842-60. 
 
 
Historic path to gastroenterology 
 
Peptic ulcer has been a disease of animals and humans since the acid producing organs 
were the means of preparing the food for absorption. In mammals, digestion and passage of 
food to be absorbed in the intestines was enabled by acid producing organs that had 
specialized epithelial cells, musculature and innervation. On the path through the hystory of 
civilisation we could observe views and perspectives of food digestion that were introduced 
by contemporary philosophers, physicians, experts and scientists, differing from era of 
agriculture, over the era of industrialization to modern times of electronic technology and 
computers.  
 
Hippocrates (5th century B.C.) introduced the term of pepsys to denote that the food was 
"cooked" and converted to four humors: blood, phlegm, yellow and black bile.1 (Figure 1) This 
view prevailed for nearly two thousands years, a time span in which almost nothing was done 
to clear the mystery of food digestion in the stomach. Teofrastus Bombastus von Hohenheim 
(Paracelsus, 1493 - 1541), a professor of medicine in Basel who also taught at Freiburg and 
Strasbourg, beleived the human diseases were caused by chemical changes governed by 
chief archeus that represented the ultimate forces of energy that governed the universe.2 
Thus, the historic path to modern gastroenterology represented a long way from these early 
philosophical observations, over the identification of gastric acidity and studies of gastric 
function in 19th century to Ismar Boas (1858 – 1938), the founder of gastroenterology as a 
specialty and the editor of the first medical journal for digestive diseases.  
 
It is almost an impossible task to describe the whole history of concepts in gastric 
pathophysiology and discoveries in etiopathogenesis of peptic ulcer disease, mentioning the 
single role of each anatomist, physiologist, researcher or clinician who contributed to 
revealing of the mechanisms of gastric acid secretion and therapy of acid related diseases. 
The authors have tried to point out the most important steps in understanding the workings of 
the stomach – from early ideas to modern concept of  molecular mechanisms of gastric acid 
secretion and mucosal protection in order to diagnose and treat peptic ulcer disease (Table 
1).        
 
Pathophysiogical concepts in gastric acid secretion  
 
In regard to the role of nerves in gastric acid secretion, it was A. Vesalius (1543) who 
described vagal nerves, "wandering" to different abdominal organs and structures.3 The story 
of gastric acid secretion had begun with early ideas on gastric secretion and process of 
digestion, described by Lazzaro Spallanzani (1729 - 1799), the Italian physiologist and Rene 
de Reaumur (1683 - 1757), the French scientist. After series of experiments conducted on 
animals and himself, Spallanzani proposed his "theory of chemical solution"(1784) by which 
the solvent called "gastric juice" (1793) was entirely neutral.4 In contrast, Reaumur concluded 
(1752) that gastric juice was acidic.5 He conducted the experiments on buzzard, a prey bird 
that was known to eject indigestible food form its stomach, and his experiments showed that 
the juice extracted form regurgitated pieces of sponge out of buzzard's stomach were 
capable of digesting meat. The experiments of Reaumur paved the way for William Prout, the 
English physiologist who provided the chemical analysis, showing the gastric juice contained 
acid – termed "muriatic acid" -  that was later identified to be hydrochloric acid.6  
The first descriptions of gastric physiology of food digestion were made by French scientists 
Dupuytren and Bichat (1801) in Paris, who observed gastric fistula of Madeline Gore, after 
she fell down stone stairs at age 20 years;  and William Beaumont, the US Army surgeon, 
who studied Alexis St. Martin's gastric fistula (1823 – 1833), acquired after a gunshot wound, 
in 1822.7 During 19th century and early 20th century, the investigation of the morphology and 
fine structure of the stomach answered the question of the source of gastric acid: Johannes 
Purkinje gave the first description of gastric glands and principal cell types (light microscopy, 
1837), Camillo Golgi noted the marked change of glands and parietal cells by digestive 
stimulus (1893 / 1895) and Dalton and colleagues documented the fine structure of gastric 
epithelial cells, including parietal cells (1951) (Figure 2).8,9  
Almost paralleling the investigations of stomach glands' morphology and acidic nature of 
gastric juice were the studies on physiological concepts of gastric secretion, in late 19th and 
early 20th century. In St. Petersburg, I.P. Pavlov was the first to demonstrate that gastric acid 
secretion in fasted dogs starts following exposure to appetizing food even without the 
passage of this food into the stomach, using eosophageal and gastric fistulas in dogs 
("sham-feeding", 1895).10 For his theory of "nervism" - the neuro-reflex stimulation of 
digestive secretion by n. vagus - he was awarded Nobel prize in 1904. The works of L. 
Popielski, a Polish pharmacologist at the Lvov University (1920) and C.F. Code (1956) 
revealed the histamine mediated concept of gastric secretion, as an alternative to 
"nervism".11,12 The discovery of gastrin by J. S Edkins (1905) and its isolation and synthesis 
by R. Gregory and H. Tracy (1964) was followed by experiments of B. Uvnas and L. Olbe, 
demonstrating the role of gastrin in acid secretion by the fact that removal of gastric antrum – 
the major source of gastrin – greatly attenuated gastric secretory response to sham-
feeding.13,14,15 Theodor Schwann at Berlin described a water-soluble factor in gastric juice 
that was capable of digesting egg-white (1836), and he called it "pepsin", after the Greek 
word for digestion.16 The possible existence of a pro-enzyme, pepsinogen was formally 
postulated by Epstein and Grutzner (1854) and, in a series of publications (1879 – 1882) J.N. 
Langley at Cambridge established the basic morphology and secretory characteristics of  the 
pepsin-forming glands in the stomach that contained pepsinogen.17 Langley also coined the 
term "oxyntic" to identify the role of the acid secreting cells in gastric mucosa. R.P 
Heidenhein, a professor of physiology at Breslau continued the study of pepsin (1878) and 
also described a "third" type of cells, which adhered to external surface of epithelial cells, that 
100 years later would be identified as enterochromaffine-like cells (ECL), responsible for 
biosynthesis of histamine.18 These discoveries have shown that gastric acid and pepsin are 
essential for process of food digestion in the stomach, and also pointed to histamine, being 
the most potent gastric acid secretagogue and final common chemostimulator of oxyntic cells. 
In addition, it was found that histamine is released from ECL cells upon stimulation by food 
and other gastric secretagogues, such as gastrin. However, there existed the unresolved 
questions of regulation and mechanisms of acid secretion or "how does it happen", and 
physiologic gastric secretion profile or "how does it look like". Preceeded by A. Kay of 
Glasgow who developed the augmented histamine test, W. Card and I.N. Marks of the 
Western General Hospital in Edinburgh (1960) were able to establish that maximal acid 
output correlated with parietal cell mass.19 Gerhard Katsch of Greiswald introduced 
quantitative function tests with caffeine / histamine in order to evaluate gastric secretory 
capacity for hydrochloric acid (1925) 20 
 
By 1960s a long list of antihistaminic agents had been proposed and studied, without 
identification of an agent effective in the inhibition of acid secretion. 
Following the pioneering work of Sir Henry Dale in isolation and function of histamine, Sir 
James Black, a pharmacologist working for Smith Kline and French in England proposed that 
there existed a homogenous population of non-H1 receptors in gastric mucosa that he chose 
to term "H2" receptors, and announced that compound burimamide (1972), which posessed 
an imidazole ring with side chain was capable to inhibit the secretion of gastric acid.21 These 
new H2-receptor antagonists were found to inhibit histamine-induced gastric secretion, as 
well as the gastric secretion provoked by meal or vagal excitation.22 Development of the 
concept of H2 receptor antagonists and their therapeutic utility was major factor in gaining Sir 
James Black the Nobel prize for Medicine or Physiology in 1988.  
 
Still, the key question was unanswered: how does the stimulation by vagal nerves, gastrin or 
histamine, acting via the membrane receptors and intracelullar mediators provoke the gastric 
acid secretion? The experiments on bullfrog oxyntic cells by A.L. Ganser and J.G Forte in 
USA were able to demonstrate the existence of a unique enzyme in the parietal cell: a 
potassium – stimulated adenosine triphosphatase (K+-ATPase) which was later identified, 
also in mammals and humans as the final step in acid secretion – the acid pump.23 In studies 
that followed, G. Sachs and coworkers elucidated that there are about 1 billion (109) parietal 
cells in the healthy stomach, being characterised by a large number of mitochondria that 
provide ATP to drive acid secretion process, and having tubulovesicles and secretory 
canaliculi, as well. They have also shown that upon activation of parietal cell much of 
tubulovesical membrane is inserted into secretory canalicular membrane, carrying with it 
many acid pumps and greatly increasing acid secretion by activation of the proton or acid 
pump (H+,K+-ATPase): for each H+ ion pumped out of the cell, a K+ ion is pumped in, 
resulting in a significant pH gradient – from pH 7.3 inside the parietal cell cytosol to pH 1.0 in 
the secretory canaliculi.24 When the parietal cell is stimulated, an increase in permeability of 
the apical membrane for chloride (Cl-) ions occurs and diffusion of chloride ions into secretory 
canaliculi takes place, but  unlike K+ ions, the chloride ions are not pumped back into parietal 
cell.24 The discovery of location, nature and molecular structure of the acid pump led to 
development of products that acted directly on the acid pump: CMN 131 
(pyridylmethylthioacetamide) in 1971 and its derivative timoprazole in 1974, picoprazole in 
1976 and ultimately to omeprazole in 1979.25 Omeprazole is a prodrug and a weak base with 
high affinity for acidic space close to the acid pump where it is rapidly converted into 
sulphenamide, which forms a covalent complex with the acid pump enzyme that results in 
effective acid inhibition, irrespective of the type of stimulus acting on parietal cell.26 Following 
the first discoveries, the human energy and resources of many pharmaceutical companies 
were focused on development of compounds that would rapidly end effectively act on acid 
pump enzyme, outlining the group of potential proton pump inhibitors, of which many were 
thrown to healthcare market and have been used for treatment of patients with acid related 
disorders. 
  
 
Discoveries in etiopathogenesis of mucosal injury and peptic ulcer disease 
 
Dragutin (Carl) Schwarz (Varazdin, Croatia 1868 – Vienna, Austria 1917) was the unique 
figure in clinical research in regard to the role of gastric acid in etiopathogenesis of peptic 
ulcer disease. With his works as a surgeon, he contributed to surgical therapy and pathology 
of penetrating gastric ulcer.27 However, in regard to historical impact to drive research in 
peptic ulcer disease Schwarz has been remembered for his famous dictum: "No acid, no 
ulcer" ("Ohne saueren Magensaft kein peptisches Geschwuer", 1910), that has been strongly 
influencing peptic ulcer research till nowdays.28  
At the beginning of 20th century, it was believed that the stomach wall harbours an intrinsic 
property  that was capable of resisting digestion with gastric acid, the so-called "vital spirit", 
and that the breakdown of a such vital force is responsible of mucosal damage and ulcer 
formation.29 In the early 1930s, T. Teorell proved that surface epithelial cells and adherent 
mucus containing bipolar phospholipids prevent the ionized mineral acids, such as 
hydrochloric acid, from back-diffusing from gastric lumen into the mucosa, due to high 
polarity of phospholipids.30 On the contrary, the unionized organic compounds, such as byle 
salts or aspirin, with a relatively low pKa, can rapidly reach surface mucosal cells by non-
ionic diffusion to accumulate in their interior, dissociate in neutral surroundings and to cause 
mucosal damage.30 This observations suggested that mucosal injury occurs regularly, but 
does not lead to clinically significant disruption of the function, implicating that "mucosal 
defense" consists of several components or "layers", with secondary components becoming 
more important when more superficial components are breached. H. Davenport and C. Code 
are responsible for coining  the term "gastric mucosal barrier" (1955) , and together with J. F. 
Scholer  they proposed that breaking of the barrier represents the initial step in the process 
of mucosal injury.31,32  
Untill 1970s, peptic ulcer was believed to be the result of corrosive effects of gastric acid, and 
in 1980s and 1990s the term of "mucosal defence" was delineating various factors and 
components  that permit the gastric mucosa to remain intact despite its frequent exposure to 
substances with wide range of temperature, pH, and osmolarity, as well as to substances 
with detergent or cytotoxic action, and bacterial products capable of causing local and 
systemic inflammatory reactions.33 The works of J.R. Vane and A. Robert documented that 
prostaglandins (a group of fatty acids first isolated from seminal fluids by Von Euler, in 1936) 
modulate virtually every aspect of gastric mucosal defence.34 Vane, who was later awarded 
the Nobel prize, described the finding that aspirin and other NSAIDs inhibited the synthesis 
of prostaglandins in the gastric mucosa (1971) and Robert (1976) documented that 
prostaglandins, in doses well below those necessary for inhibiting gastric acid secretion 
showed  the protective effect against oral administration of necrotizing agents.35,36 Later on, 
the prostaglandins were shown to influence major components of gastric mucosal barrier: 
they maintain the integrity of epithelium and mucosal blood flow, also being the potent 
inhibitors of leukocyte adherence to endothelium in mucosal inflammation, as well as the 
promotors of ulcer healing. They enhance bicarbonate and mucus secretion and decrease 
gastric mucosal barrier permeability and acid back-diffusion.37 This remarkable ability of 
prostaglandins  to reduce the gastric mucosal injury was described with term "cytoprotection", 
that was coined by A. Robert, at the suggestion of E. Jacobson. 
   
Beginning in the latter half of 19th century, the studies on gastric bacteriology that followed 
paved the way for discovery of association between Campylobacter (Helicobacter) pylori and 
peptic ulcers by Robin Warren (1979) and Barry Marshall (1982). German scientists G. 
Bottcher and French scientist M. Letulle demonstrated bacterial colonies in the ulcer floor 
and its mucosal margins (1875), being first to postulate the causation of ulcers to the bacteria 
which they could demonstrate, followed by W. Javorski at Cracow, who discovered and 
postulated a pathogenic role for the spiral organism (Vibrio rugula) he found in gastric 
contents (1896), and I. Boas at Berlin, who co-discovered the Oppler-Boas bacterium, which 
he tought was implicated in etiology of gastric carcinoma.38 Almost paralleling the research of 
gastric bacteria, the importance of vagal nerve in gastric pathophysiology was widely 
accepted, especially after Dragstedt's pionerring work on the role of vagotomy in the 
treatment of peptic ulcers.39 Interestingly, in his first paper that was published in 1917, in the 
same year when C. Schwarz died in Austria, Dragstedt described the bacterial model of 
gastric and duodenal ulcers, revealing the posibility of growing bacteria from these ulcers.40 
Further studies of A. Kussmaul (1869), C. Golgi (1893), K. Shiga (1898), Krienitz (1906), 
Hoffman (1925), Saunders (1930), Freedberg and Barron (1941) and Gorham (1940s) were 
all speaking of bacteria in the stomach, that subsequently led to the study of E.D. Palmer on 
gastric samples from 1180 subjects, using standard histological techniques (1950s) that 
failed to demonstrate the presence of bacteria in the stomach.38 Palmer concluded that the 
results of all previous authors were the sequels of post mortem colonization of the gastric 
mucosa with oral cavity organisms.  
 
Robin Warren, a pathologist at the Royal Perth Hospital and a young gastroenterology fellow 
Barry Marshal described the association of S-shaped Campylobacter-like organism and 
histological changes in 135 gastric biopsy specimens (1983), and by fulfilling the 
requirements of four Koch's postulates demonstrated the infectious nature of provoked 
gastritis.41 With this discovery began the modern Helicobacter era leading to the fact that H. 
pylori represents a major etiopathogenetic factor for gastroduodenal pathology: acute and 
chronic gastritis, peptic ulcer, gastric cancer and MALT lymphoma. The notion that the 
prevalence of H. pylori associated gastritis and its sequels should be regarded as an 
infectious disease led to worldwide major interventions, such as use of antibiotics in 
eradication therapy for H. pylori and attempts in vaccine development, as well.      
 
Old and new therapies: modalities of acid inhibition 
Beside chalk and pearl juleps, throughout 17th century and in early 19th century there was 
no record on specific remedies for gastric diseases. Cruveilhier at Paris had written 
extensively on  the pathology of peptic ulcer disesae, but in those times little specific therapy 
apart form dietary adjustments or homeopatic remedies were apparent. Glycerrhetinic acid, a 
constituent of liquorice was used as a folk remedy for peptic ulcer disease, and in the latter 
half of 19th century physicans were treating peptic ulcer by using the extract of beladona, 
containing atropine, a nonselective muscarinic antagonists with intolerable side-effects, such 
as blurred vision, dry mouth and bladder dysfunction.42 B Sippy (1915) and R. Doll introduced 
bland diets in the treatment of patients with peptic ulcer, augmented with the addition of 
neutrilizing compounds and antacids. However, such regimens lead to significant decline in 
the quality of life and significant side effects that even surgery became a reasonable option.43  
 
Surgical approach to peptic ulcer had been confounded for years by the problems related to 
sepsis and lack of anesthesia, problems of perioperative morbidity and mortality, as well as 
the problems of  "post gastrectomy syndromes". Nevertheless, the resection procedures, 
devised by Billroth (1881), Pean, Moynihan and Ridiger were capable of removing the 
ulceration, also  providing relief of pain, bleeding, perforation and stenosis. However, 
alternative strategies to decrease secretion of acid were developed: M. Jaboulay of France 
performed the first vagotomy in a human patient (late 19th century), later combining 
vagotomy with a gastrojejunostomy to promote gastric emptying, followed by M.A. Latarjet in 
Lyons (1921) and L. Dragstedt (1943), in Chicago.44  
Antacids, protective agents, anticholinergics, and later gastrin antagonists and 
prostaglandins were used for decades in treatment of peptic ulcer, with differing effects. The 
advent of the concept of H2 receptor antagonists in late 1970s denoted the end of "before 
cimetidine" era, due to the results of clinical studies that documented that these drugs were 
effective for pain relief of ulcer pain and for ulcer healing, as well as in continued use being 
effective in reducing the ulcer recurrence.45 A standard single dose of an H2 antagonists 
taken at bedtime (e.g. cimetidine 800 mg, ranitidine 300 mg, , famotidine 40 mg, or nizatidine 
300 mg) would be expected to heal about 80% of duodenal ulcers after 4 weeks, a proportion 
that increases to 95% after a total of 8 weeks.46 Healing of gastric ulcers with H2 receptors 
usually takes longer: 65% to 70% after 4 weeks and 85% to 90% after 8 weeks.47 However,  
the development of pharmacologic tolerance to all available H2 antagonosts in prolonged 
therapy had been observed in early 1990s, especially limiting the use of these drugs in 
maintenance therapy for acid related disorders.48  
 
The proton pump inhibitors (the irreversible inhibitors of the enzyme H+ /K+ -ATPase) were 
associated with higher rates and faster duodenal ulcers healing (90% after 4 weeks), as well 
as higher rates and faster gastric ulcers healing (approximately 90% after 4 weeks), 
providing a greater degree of inhibition of gastric acid secretion than did conventional doses 
of  the H2  antagonists.
49 In addition, PPIs have been proven to be a successfull treatment in 
patients with Zollinger-Ellison syndrome, and in healing of  gastric ulcers in patients who 
continue to use NSAIDs.50 Noteworthy, inhibiton of acid secretion with PPIs is never 
complete because new molecules of acid pump are constantly being synthesized, and 
therefore, PPIs do not induce achlorhydria.51 Early concerns in regard to formation of 
carcinoid tumors, derived from ECL cells in rats on prolonged use of high doses of PPIs had 
not been encountered in routine clinical use of PPIs.52 Thus, H2 antagonists had been proven 
to be more effective in inhibiting acid secretion in basal state (fasting or overnight), than in 
response to food digestion, and PPIs offered strong reduction of basal and stimulated acid 
output, beeing effective to maintain gastric juice in pH >3 to pH >5, in duration of 8 – 16 
hours, providing optimal treatment for acid related disorders.53   
  
The role of endoscopy 
 
The low prevalence of peptic ulcer that had been documented during 19th century may be 
atributed to an inability at the time to diagnose uncomplicated peptic ulcer during the patient's 
life: the statistics were mostly based on autopsy studies.54 Adolf Kussmaul (1822 – 1902) at 
University of Freiburg performed the first gastroscopy ever (1868), by introducing his 
endoscope into the stomach of the sword swallower.55 Nevertheless, from 1910 to 1970, the 
methods of radiology were superior to endoscopy in diagnosing peptic ulcer. Using the side-
viewing endoscope, devised by Elsner (1910 / 1911), Rudolf Schindler successfully 
performed gastroscopies that resulted in his first published book on gastroscopic diagnosis 
("Lehrbuch und Atlas der Gastroskopie", 1923).56 In 1932, Schindler introduced the 
semiflexible Wolf-Schindler gastroscope into clinical practice, but still, there was a problem of 
difficulty of passage, limitations of viewing, and continuing risk of injury.57 In 1954, the 
dicoveries of image transmission through a flexible bundle of oriented glass fibers - termed a 
"fiberscope" - by Hopkins and Kapany, followed by development of Hirschowitz's prototype of 
first fiberscope for clinical use (1957), enabled the commercial production of gastroduodenal 
fiberscope by American Cystoscope Makers, Inc. (ACMI), in 1960.58 Since the 1970s, the 
endoscopy has been the gold standard for diagnosing ulcer, healing and relapse in a 
multitude of clinical trials of ulcer treatment. Further development of electronic video 
technology enabled the advent of videoendoscopy (Welch-Allyin Inc, 1983), that 
revolutionized the methods of teaching in gastrointestinal endoscopy.59   
The burden of peptic ulcer in the society may be outlined by its association with the 
prevalence of H. pylori in a certain population, the prevalence of comorbid conditions and 
chronic medication, as well as the risk factors, making the patients prone to development of 
peptic ulcer. Nowdays, we have witnessed the new techniques and methods of endoscopy 
and endosonography that have been brought into clinical practice, highlighting the possibility 
of imaging beyond white light and beyond mucosal layer, as well. 
 
Society and Healthcare    
  
The burden of peptic ulcer in the society may be outlined by its association with the 
prevalence of H. pylori in a certain population, the prevalence of comorbid conditions and 
chronic medication, as well as the other risk factors, making the patients prone to 
development of peptic ulcer. Nevertheless, the lifetime risk for peptic ulcer in patients with H. 
pylori infection is 3% to 25%, the overall risk  being greater in NSAID users (OR 6.1) than in 
NSAID users without H. pylori infection (OR 4.8).60 There has also been some data, pointing 
out to possible association of peptic ulcer to other conditions with significant impact on the 
society: anxiety disorder (OR 3.43), panic disorder (OR 3.11), dysthymia (OR 3.59) and 
bipolar disorder (OR 2.91).61 However, nicotine and alcohol dependence  seems to play a 
substantial role in explaining the link of these disorders to peptic ulcer disease. Interestingly, 
the Italian authors even observed a significant reduction in sperm motilitiy with increased 
systemic levels of TNFα levels in CagA- positive infertile patients with H. pylori infection, but 
it seems these results need further clarification.62  
Peptic ulcer remains a common condition, although reported incidence and prevalence is 
decreasing, and this decrease may be due to decrease in H. pylori associated peptic ulcer 
disease.63 However, the 1-year prevalence of peptic ulcer has been reported ten times 
greater in patients aged 75-84 years (0.40%) than in patients aged 0-35 years (0.04%).64 A 
Danish study reported a decrease of overall incidence of peptic ulcer that was accompanied 
by an increase of peptic ulcers potentially related to NSAID use from 39% in 1993 to 53% in 
2002 (p < 0.01), and a study from The Netherlands documented that admission rates for 
complications of PUD remained fairly stable in men and increased slightly in women, over 
the period 1980 – 2003.65,66 In the USA (2004), peptic ulcer was first-listed diagnosis at 
hospital discharge in 37% of cases, and nearly 80% of deaths related to peptic ulcers 
occurrred among people aged ≥ 65 years.67 In regard to total costs of digestive diseases in 
the USA (2004), the total costs of both, PUD and GERD were leveling to about 60% of total 
costs for all digestive cancers and, interestingly, PPIs represented 50.6% of prescriptions 
and 77.3% of costs of retail pharmacy sales for all digestive diseases.67 Worldwide, peptic 
ulcer and its complications thus remain the cause of  significant morbidity, especially in older 
age groups, representing a major burden for ambulatory and hospital healthcare resources. 
Never to be forgotten, all our efforts as gastroenterologists have been aimed to well being of 
our patients, throughout patients' journey in the circles of diagnosis and treatment (Figure 3). 
If it is not possible to cure the disease entirely, our task is the improvement of patient's 
health-related quality of life. 
   
 
Conclusions and "A view to the future" 
 
Being an interface to "outer world", the gastroduodenal mucosa has been under constant 
attack during the era of human civilization, and its homeostasis is essential for living a 
healthy life. The history of medicine has taught us that gastric acid secretion plays a major 
role in pathophysiology of PUD. During past 50 years we have witnessed the major 
discoveries in etiopathogenesis of PUD, as well as the advent of potent acid inhibitors and 
advances in methods and techniques of upper GI endoscopy. Just to mention the few, the 
open questions that remain are do we need the special approach for cohorts of parients, who 
are at special risk for PUD and do we need the more powerful / prolonged acid inhibition. 
Maybe, the study of genetics and epigenetics would lead to improved protocols for 
eradication of H. pylori infection and to effective prevention of gastric atrophy. Looking back, 
we should realize that there is at least so much to learn in front of us, as there was behind.  
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Table 1  Major historical impacts to drive research in peptic ulcer disease 
 
EARLY OBSERVATIONS Hippocrates (5th century B.C.): 
pepsys : the food was "cooked" in the stomach 
Paracelsus (1493-1541): archei:ultimate forces of enery governing humans and 
universe 
A. Vesalius (1543): first description of vagal nerves  
PATHOPHYSIOLOGICAL 
CONCEPTS IN GASTRIC 
ACID SECRETION 
 
Early ideas: gastric juice and 
gastric acid 
R. de Reaumur (1752): acidic nature of gastric juice 
L. Spallanzani (1793): gastric juice as chemical solvent 
W. Prout: "muriatic acid" in stomach contents, later identified to be hydrochloric acid  
Gastric phyisiology of food 
digestion 
Dupuytren and Bichat (1801) and W Beaumont (1823): accidentally acquired 
gastric fistulas as "a window"  to observe the process of food digestion  
Morphology and fine structure 
of stomach glands 
J Purkinje (light microscopy, 1837): first description of gastric glands 
C. Golgi (1893): marked changes of stomach glands upon digestive stimulus 
Dalton (1951): fine structure of gastric parietal cells 
Phisyological concepts of 
gastric secretion 
I.P Pavlov (1895): neuro-reflex stimulation of gastric secretion by vagal nerve 
L. Popielski (1920) and C.F. Code (1956): histamine mediated concept of gastric 
secretion 
J.S. Edkins (1905): the discovery of gastrin 
T. Schwann (1836): the discovery of pepsin 
DISCOVERIES IN 
ETIOPATHOGENESIS OF 
MUCOSAL INJURY AND 
PEPTIC ULCER 
 
Gastric acid and gastric 
mucosal barrier 
D.K. Schwarz (1910): dictum "No acid, no ulcer" 
T. Teorell (1930s): "back-diffusion" of acid causes mucosal damage 
H. Davenport / C. Code / J. Scholer (1955): the concept of "gastric mucosal barrier" 
Prostaglandins (PGs) and 
"gastric cytoprotection" 
J.R Vane (1971) and A. Robert (1976): PGs modulate the gastric mucosal defence 
A. Robert and E Jacobson (1970s): PGs reduce gastric mucosal injury – 
"cytoprotection" 
Bacteria in the stomach G. Bottcher and M. Letulle (1875): documented bacterial colonies in ulcer floor and 
mucosal margins 
W. Jaworski (Vibrio rugula, 1896) and I. Boas (Oppler-Boas bacterium): postulated a 
pathogenic role of bacteria in gastric ulcer and gastric carcinoma 
E.D. Palmer (1950s): failed to demonstrate the presence of bacteria in the stomach 
R. Warren and B. Marshall (1983): the discovery of Helicobacter (Campylobacter) 
pylori in gastric mucosa 
OLD AND NEW 
THERAPIES: MODALITIES 
OF ACID INHIBITION 
 
Old therapies 17th to early 19th century: no record on specific remedies for gastric diseases 
19th century physicians: use of extract of beladona (atropine) for treating peptic 
ulcer, with intolerable side-effects 
B. Sippy (1915) and R. Doll: introduced bland diets and antacids in treatment of 
peptic ulcer 
20th century: use of anticholinergics, gastrin antagonists and PGs in peptic ulcer 
treatment, with differing effects 
Surgical approach to treating of 
peptic ulcer 
Billroth (1881), Pean, Moynihan, Ridiger: gastric resection procedures 
M. Jaboulay (late 19th century): first vagotomy in human patient 
M. Jaboulay, M.A. Latarjet (1921), L. Dragstedt (1943): vagotomy with 
gastrojejunostomy to promote gastric emptying 
 
Advent of potent inhibitors of 
gastric acid secretion 
Sir J. Black (1972): the concept of H2-receptor antagonists as potent inhibitors of 
gastric secretion 
A.L. Ganser and J.G. Forte (1970s): the discovery of K+-ATPase in bullfrog oxyntic 
cells 
G. Sachs and coworkers (1970s and 80s):  dicovery of location, nature and molecular 
structure of acid pump / synthesis of  first PPIs 
 
Figure 1 
By term pepsys Hippocrates (5th century B.C.) denoted that food was "cooked" in the 
stomach 
 
    
 
 
 
 
Figure 2 
Camillo Golgi noted the marked change in appearance of gastric glands upon 
stimulation (1893 / 1895): resting gland (a) and stimulated gland (b) 
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Figure 3 
The patients' "Journey" 
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